

RÉFÉRENCES DE PUBLICATIONS DANS DES REVUES À COMITÉ DE LECTURE - ANNÉE 2015

1. *Annequin M, Weill A, Thomas F, Chaix B. *Environmental and individual characteristics associated with depressive disorders and mental health care use. Ann Epidemiol. 2015 Feb 13. pii: S1047-2797(15)00048-4. doi: 10.1016/j.annepidem.2015.02.002*
2. Raguideau F, Mezzarobba M, Zureik M, Weill A, Ricordeau P, Alla F. Compliance with pregnancy prevention plan recommendations in 8672 French women of childbearing potential exposed to acitretin. *Pharmacoepidemiol Drug Saf. 2015 May;24(5):526-33. doi: 10.1002/pds.3763. Epub 2015 Mar 9.*
3. Piolot M, Fagot JP, Rivière S, Fagot-Campagna A, Debeugny G, Couzigou P, Alla F. Homeopathy in France in 2011-2012 according to reimbursements in the French national health insurance database (SNIIRAM). *Fam Pract. 2015 Aug;32(4):442-8. doi: 10.1093/fampra/cmz028. Epub 2015 Apr 28.*
4. Bouillon K, Bertrand M, Maura G, Blotière PO, Ricordeau P, Zureik M. Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study. *Lancet Haematol. 2015 Apr;2(4):e150-9. doi: 10.1016/S2352-3026(15)00027-7. Epub 2015 Apr 1.*
5. *Fosse-Edorh S, Fagot-Campagna A, Detournay B, Bihan H, Eschwege E, Gautier A, Druet C. *Impact of socio-economic position on health and quality of care in adults with Type 2 diabetes in France: the Entred 2007 study. Diabet Med. 2015 Nov;32(11):1438-44. doi: 10.1111/dme.12783. Epub 2015 May 8.*
6. Chaignot C, Weill A, Ricordeau P, Alla F. [Use in France of Baclofen for Alcohol Dependence from 2007 to 2013: Cohort Study Based on the Databases SNIIRAM and PMSI]. *Therapie. 2015 Sep-Oct;70(5):443-53. doi: 10.2515/therapie/2015027. Epub 2015 Jun 26. French.*
7. Maura G, Blotière PO, Bouillon K, Billionnet C, Ricordeau P, Alla F, Zureik M. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. *Circulation. 2015 Sep 29;132(13):1252-60. doi: 10.1161/CIRCULATIONAHA.115.015710. Epub 2015 Jul 21.*
8. Basson M, Mezzarobba M, Weill A, Ricordeau P, Allemand H, Alla F, Carbonnel F. Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study. *Gut. 2015 Aug 6. pii: gutjnl-2015-309690. doi: 10.1136/gutjnl-2015-309690*
9. Cosker K, Samson S, Fagot-Campagna A, Woimant F, Tuppin P. First hospitalization for transient ischemic attack in France: Characteristics, treatments and 3-year outcomes. *Rev Neurol (Paris). 2015 Aug 26.*
10. *Cloix L, Caille A, Helmer C, Bourdel-Marchasson I, Fagot-Campagna A, Fournier C, Lecomte P, Oppert JM, Jacobi D. *Physical activity at home, at leisure, during transportation and at work*

in French adults with type 2 diabetes: the ENTRED physical activity study. Diabetes Metab. 2015 Feb;41(1):37-44. doi: 10.1016/j.diabet.2014.07.003. Epub 2014 Sep 30.

11. Roussel R, Chaignot C, Weill A, Travert F, Hansel B, Marre M, Ricordeau P, Alla F, Allemand H. Use of Fibrates Monotherapy in People with Diabetes and High Cardiovascular Risk in Primary Care: A French Nationwide Cohort Study Based on National Administrative Databases. PLoS One. 2015 Sep 23;10(9):e0137733. doi: 10.1371/journal.pone.0137733. eCollection 2015.
12. Aguade A, De Lagasnerie G, Denis P, Gastaldi-Menager C, Fagot-Campagna A, Gissot C, Polton D. Estimating The Burden Of Diabetes To The French National Health Insurance. Value Health. 2015 Nov;18(7):A387-8. doi: 10.1016/j.jval.2015.09.850. Epub 2015 Oct 20.
13. Filipovic-Pierucci A, Cuerq A, Samson S, Tala S, Fagot-Campagna A, Tuppin P. Consommation de soins et mortalité des bénéficiaires de la CMU-C dans les départements français d'outre-mer en 2012, et comparaisons avec la France métropolitaine. Bull Epidemiol Hebd. 2015;(38-39):733-41.

** Ces études ont été réalisées par des équipes extérieures à l'Assurance Maladie, avec l'appui et la participation de la Cnamts.*